234 related articles for article (PubMed ID: 38194088)
1. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U
Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics and Diagnosis of Acute Myeloid Leukemia with CD56-Blastic Plasmacytoid Dendritic Cell Neoplasm.
Zhang X; Wu Y; Li C; Shen K; Li R
Clin Lab; 2023 Jun; 69(6):. PubMed ID: 37307129
[TBL] [Abstract][Full Text] [Related]
3. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A; Sweet K
J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
[TBL] [Abstract][Full Text] [Related]
4. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
Riaz W; Zhang L; Horna P; Sokol L
Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous Remission of Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.
Castaño-Bonilla T; Mata R; Láinez-González D; Gonzalo R; Castañón S; Díaz de la Pinta FJ; Blas C; López-Lorenzo JL; Alonso-Domínguez JM
Medicina (Kaunas); 2024 May; 60(5):. PubMed ID: 38792990
[TBL] [Abstract][Full Text] [Related]
6. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
[TBL] [Abstract][Full Text] [Related]
7. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow.
Alayed K; Patel KP; Konoplev S; Singh RR; Routbort MJ; Reddy N; Pemmaraju N; Zhang L; Shaikh AA; Aladily TN; Jain N; Luthra R; Medeiros LJ; Khoury JD
Am J Hematol; 2013 Dec; 88(12):1055-61. PubMed ID: 23940084
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm.
Wang W; Khoury JD; Miranda RN; Jorgensen JL; Xu J; Loghavi S; Li S; Pemmaraju N; Nguyen T; Medeiros LJ; Wang SA
Haematologica; 2021 Apr; 106(4):1047-1055. PubMed ID: 32241840
[TBL] [Abstract][Full Text] [Related]
9. Comparison and Development of Immunohistochemical Diagnostic Criteria for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Sakamoto K; Baba S; Okumura Y; Momose S; Ono S; Tonooka A; Ichinohasama R; Takakuwa E; Nakasone H; Ohshima K; Takeuchi K
Mod Pathol; 2023 Oct; 36(10):100253. PubMed ID: 37380058
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.
Economides MP; Konopleva M; Pemmaraju N
Ther Adv Hematol; 2019; 10():2040620719874733. PubMed ID: 31579499
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological analysis of 46 cases with CD4
Suzuki Y; Kato S; Kohno K; Satou A; Eladl AE; Asano N; Kono M; Kato Y; Taniwaki M; Akiyama M; Nakamura S
Histopathology; 2017 Dec; 71(6):972-984. PubMed ID: 28795410
[TBL] [Abstract][Full Text] [Related]
12. Plasmacytoid dendritic cell neoplasms.
Lee YJ; Kim Y; Park SH; Jo JC
Blood Res; 2023 Apr; 58(S1):90-95. PubMed ID: 37105563
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
[TBL] [Abstract][Full Text] [Related]
14. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
Zhang X; Sun J; Yang M; Wang L; Jin J
Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
[TBL] [Abstract][Full Text] [Related]
15. Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression.
Gulati R; Abu-Salah A; Salous T; Nassiri M
J Hematop; 2022 Mar; 15(1):35-39. PubMed ID: 38358597
[TBL] [Abstract][Full Text] [Related]
16. Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches.
Cheng W; Yu TT; Tang AP; He Young K; Yu L
Curr Med Sci; 2021 Jun; 41(3):405-419. PubMed ID: 34218354
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm.
Wang W; Xu J; Khoury JD; Pemmaraju N; Fang H; Miranda RN; Yin CC; Hussein SE; Jia F; Tang Z; Hu S; Konopleva M; Medeiros LJ; Wang SA
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884435
[TBL] [Abstract][Full Text] [Related]
19. Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects.
Trottier AM; Cerquozzi S; Owen CJ
Blood Lymphat Cancer; 2017; 7():85-93. PubMed ID: 31360087
[TBL] [Abstract][Full Text] [Related]
20. A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
Song J; Li W; Bai Y; Zhou P; Niu J; Niu X; Liu Y; Liu X; Drokow EK; Sun K; Zhou H
Ann Hematol; 2024 Feb; 103(2):463-473. PubMed ID: 38183444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]